BioAge Labs, Inc. (BIOA) income statement
BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.28−0.43 (-9.13%)
Close on Nov 20, 2026Market cap $196.44MP/E –Yield –
BioAge Labs, Inc. financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $196.44MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Margins | ||||
| Operating margin | -1,031.5% | – | – | – |
| Pre-tax margin | -896.1% | – | – | – |
| Net profit margin | -896.1% | – | – | – |
| Free cash flow margin | -915.5% | – | – | – |
| Returns on capital | ||||
| Return on equity | -27.1% | -95.0% | 44.7% | – |
| Return on assets | -24.7% | -37.0% | -246.3% | – |
| Return on tangible assets | -24.7% | -37.0% | -246.3% | – |
| Return on invested capital | 503.4% | 60.7% | 21.1% | – |
| Return on capital employed | -30.7% | -52.4% | 150.1% | – |
| Return on total capital | -30.6% | -90.7% | 30.4% | – |
| NOPAT | -$73.30M | -$61.77M | -$38.24M | – |
| Cash flow quality | ||||
| OCF / Sales | -907.5% | – | – | – |
| OCF / Net income | 1.01 | 0.72 | 0.59 | – |
| FCF / OCF | 100.9% | 100.7% | 100.4% | – |
| FCF / Net income | 1.02 | 0.73 | 0.59 | – |
| Unlevered free cash flow | -$81.80M | -$50.02M | -$31.37M | – |
| Levered free cash flow | -$82.35M | -$51.89M | -$37.53M | – |
| Efficiency | ||||
| Asset turnover | 0.03 | 0.00 | – | – |
| Fixed asset turnover | 11.58 | 0.00 | – | – |
| Receivables turnover | 23.39 | – | – | – |
| Days sales outstanding | 15.6 | – | – | – |
| CapEx to revenue | 8.0% | – | – | – |
| CapEx to OCF | -0.88% | -0.71% | -0.44% | – |
| Liquidity | ||||
| Current ratio | 14.24 | 12.86 | 0.44 | – |
| Quick ratio | 14.24 | 12.86 | 0.44 | – |
| Cash ratio | 13.96 | 12.76 | 0.37 | – |
| Working capital | $266.66M | $329.33M | -$32.86M | – |
| Net current asset value | $263.96M | $322.00M | -$41.29M | – |
| Leverage | ||||
| Total debt | $2.65M | $8.50M | $14.20M | – |
| Net debt | -$278.45M | -$345.85M | -$7.44M | – |
| Debt / Equity | 0.01 | 0.03 | -0.08 | – |
| Debt ratio | 0.90% | 2.4% | 54.8% | – |
| Assets to equity | 1.08 | 1.11 | -0.15 | – |
| Long-term debt to assets | 0.00% | 0.70% | 31.6% | – |
| Long-term debt to equity | 0.00 | 0.01 | -0.05 | – |
| Total debt / Capitalization | 0.96% | 2.6% | -8.9% | – |
| Long-term debt / Capitalization | 0.00% | 0.77% | -5.0% | – |
| Cash flow to debt | -3,082.6% | -606.0% | -263.1% | – |
| Interest coverage | ||||
| EBIT / Interest expense | -133.11 | -33.04 | -6.21 | – |
| Per share | ||||
| Revenue per share | 0.24 | 0.00 | – | – |
| EPS (basic) | -2.24 | -6.63 | -38.17 | – |
| EPS (diluted) | -2.24 | -6.63 | -38.17 | – |
| Book value per share | 7.28 | 9.01 | -103.62 | – |
| Tangible book value per share | 7.28 | 9.01 | -103.62 | – |
| Cash per share | 7.52 | 9.88 | 12.93 | – |
| Operating cash flow per share | -2.18 | -1.44 | -22.33 | – |
| Free cash flow per share | -2.20 | -1.45 | -22.43 | – |
| CapEx per share | 0.02 | 0.01 | 0.10 | – |
| Valuation at period end | ||||
| Market cap | $474.30M | $198.00M | – | – |
| Enterprise value | $192.64M | -$126.53M | – | – |
| P/S | 52.7x | – | – | – |
| P/B | 1.7x | 0.6x | – | – |
| P/TBV | 1.7x | 0.6x | – | – |
| P/OCF | -5.8x | -3.8x | – | – |
| EV/Sales | 21.4x | – | – | – |
| EV/EBIT | – | 1.6x | – | – |
| EV/OCF | -2.4x | 2.5x | – | – |
| EV/FCF | – | 2.4x | – | – |
| Earnings yield | -17.0% | -35.9% | – | – |
| FCF yield | -17.4% | -26.2% | – | – |
| Shareholder yield | ||||
| Debt paydown yield | 1.3% | 3.0% | – | – |
| Cost structure | ||||
| R&D to revenue | 822.3% | – | – | – |
| Stock-based comp to revenue | 130.0% | – | – | – |
| Per employee | ||||
| Total employees | 62 | 64 | 64 | 64 |
| Revenue per employee | $145.08K | $0 | – | – |
| Operating profit per employee | -$1.50M | -$1.22M | -$756.25K | – |
| Net income per employee | -$1.30M | -$1.11M | -$997.72K | – |
| Free cash flow per employee | -$1.33M | -$810.75K | -$586.38K | – |
| Growth | ||||
| EBIT 1Y growth | -18.7% | -61.6% | – | – |
| Net income 1Y growth | -13.4% | -11.4% | – | – |
| Diluted EPS 1Y growth | 66.2% | 82.6% | – | – |
| Operating cash flow 1Y growth | -58.4% | -37.9% | – | – |
| Free cash flow 1Y growth | -58.7% | -38.3% | – | – |
| CapEx 1Y growth | 96.4% | 120.5% | – | – |
| Total assets 1Y growth | -17.7% | 1,281.9% | – | – |
| Total equity 1Y growth | -15.8% | 286.4% | -54.0% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.